PureTech Health plc Q2 FY2026 earnings call

Rob introduced the company's refined strategy, including streamlined structure with intention to operate leaner hub post CILIA financing and voluntary delisting from NASDAQ; launching founded entities early, refined innovation focus to generate development candidates, and commitment to capital returns. Eric discussed Gallup Oncology's Phase 1b trial data of LYT200, prioritization of MDS for next study, and innovation team's work on LIFE model to generate concept stage pharma programs

No specific absolute financial performance and revenue contribution % for each product segment detailed separately; mentions founded entities like Thalia, Philia, Gallup, People with progress, and Cabemphi's economic potential

Expect operational runway at least through end of 2028 inclusive of expected participation in certain founding entity fundraisings; expect to streamline expenses and operate lean model post CILIA fundraise; aim to progress up to two development candidates over next three years from innovation engine

Excessively exposed to early performance of Cabemphi sales, any reduction in analysts' forecast of early sales can have material impact; risks associated with dilution and funding for founded entities

Q: Double-check on cash runway to 2028, inclusion of Celia trial cost, etc.

A: Cash runway at least through 2028, conservative approach, doesn't factor in realizations, includes participation in CELIA and Gallup fundraisings Q: Talks progress with funding partners for LYT100 and CELIA A: Substantially progress made, clear line of sight to completion, majority capital from external partners Q: Selection of MDS vs AML for Gallup A: Prioritized MDS due to compelling clinical data, less competition for patients, broader potential in MDS Q: Stake in Seaport post IPO, royalties A: General practice not to take board seats post IPO, have royalties beyond GLIF application Q: Concept stage assets cost, candidates, therapeutic areas A: Modest cost for concept stage, two development candidates over three years, focus on areas like CNS Q: Impact of rationalized group post Celia finance completion on runway A: Conservative runway guidance, plan for cost reduction post Celia spin-out, participation in CELIA and Gallup fundraisings Q: Value from legacy holdings A: Bucketed as legacy holdings, no material expected inflows from them for modelling purposes Q: Capital allocation and potential capital return A: Emphasis on capital returns, intention to return greater proportion of future cash generation to shareholders